

JUN 09 2008



PTO/SB/08A(10-01)  
Approved for use through 10/31/2002. OMB 651-0031  
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/048,072
Filing Date	January 25, 2002
First Named Inventor	Franchini, Genoveffa
Group Art Unit	1648
Examiner Name	Parkin, Jeffrey

Sheet 1 of 3

Attorney Docket No: 1662.018US1

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-2006/0094006A1	05/04/2006	Franchini, G. , et al.	05/01/2003
	US-5,593,972	01/14/1997	Weiner, D. B., et al.	09/21/1993
	US-5,766,598	06/16/1998	Paoletti, E. , et al.	09/07/1994
	US-5,817,637	10/06/1998	Weiner, D. B., et al.	01/13/1997
	US-5,863,542	01/26/1999	Paoletti, E. , et al.	04/05/1995
	US-7,094,408	08/22/2006	Franchini, G. , et al.	04/30/2001

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>
	WO-01/82964A1	11/08/2001	Franchini, G. , et al.	

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		"#1 Data As Treatment / #2 HIV Antibody Breakthrough in Transgenic Mice Could Prove Boon to Vaccine", TAGLine 6(4), (1999), 11 pgs.	
		"Annual Report of the Treatment Action Group", (2001), 6 pgs.	
		"Application Serial No. 10/513,257 (Atty Ref 1662.013US1) Response filed 3-10-2008 to Non-Final Office Action mailed 12-10-2007", 15 pgs.	
		"Application Serial No. 10/513,257 (Atty Ref 1662.013US1), Non-Final Office Action mailed 12-10-2007", 11 pgs.	
		"Application Serial No. 10/513,257 (Atty. Ref. 1662.013US1), Final Office Action mailed in 08-01-2007", 15 pgs.	
		"How Vaccines Prevent Diseases", CDC - Vaccines and Immunizations, [online]. [retrieved 2008-2-26]. Retrieved from the Internet: <a href="http://www.cdc.gov/vaccines/vac-gen/howvpd.htm">http://www.cdc.gov/vaccines/vac-gen/howvpd.htm</a> , 6 pgs.	
		"International search Report for corresponding PCT Application No. PCT/US03/13737", (Attorney Docket No. 1662.013WO1), (November 2, 2004), 2 pgs.	
		New Fusion Inhibitor AMD-3100 Begins Phase II", PRNewswire, <a href="http://www.natap.org/1999/june/61299.html">www.natap.org/1999/june/61299.html</a> , (05/27/1999), 3pgs.	
		"NIAID HIV Vaccine Trials Update", News from NIAID, (October 10, 1993), 5 pgs.	
		SMASH: Small Molecule NMR Conference (Small Molecules Are Still Hot)", Argonne Guest House, Argonne National Laboratory, Argonne IL (outside Chicago, IL), (1999), 4 pgs.	
		AMARA, R. R., "Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine", Science, Vol. 292, (April 6, 2001), 69-74	

EXAMINER

/Jeffrey Parkin/

DATE CONSIDERED

09/06/2008

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's priority election designation number (optional). Applicant to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/048,072
Filing Date	January 25, 2002
First Named Inventor	Franchini, Genoveffa
Group Art Unit	1648
Examiner Name	Parkin, Jeffrey

Sheet 2 of 3

Attorney Docket No: 1662.018US1

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BENSON, J., et al., "Recombinant Vaccine-Induced Protection Against the Highly Pathogenic Simian Immunodeficiency Virus SIV <sub>mac251</sub> : Dependence on Route of Challenge Exposure", <u>Journal of Virology</u> , 72(5), (1998),4170-4182	
		BEREGER, E., et al., "Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART", <u>Proc.Natl. Acad. Sci. USA Vol. 95</u> , (1998),11511-11513	
		HANKE, T., et al., "DNA multi-CTL epitope vaccines for HIV and <i>Plasmodium falciparum</i> : immunogenicity in mice", <u>Vaccine</u> , 16 (4), (1998),426-435	
		HANKE, T., "Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime", <u>Vaccine</u> , 16(5), (1998),439-445	
		HARRINGTON, M. , et al., "Hit HIV-1 hard, but only when necessary", <u>The Lancet</u> , (2000),355:2147-2152	
		KENT, S. J., "Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus", <u>Journal of Virology</u> , 72(12), (Dec., 1998),10180-10188	
		KIEPIELA, P., et al., "CD8 <sup>+</sup> T-cell responses to different HIV proteins have discordant associations with viral load.", <u>Nat Med.</u> , 13(1), (Jan., 2007),46-53	
		KILBY, J M., "Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry", <u>Nat Med Vol 4 (11)</u> , (Abstract Only), (1998),1302-1307	
		KIM, J. , et al., "Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV.", <u>J. interferon and Cytokine Res. Vol. 19</u> , (1999),77-84	
		MARTINEZ-PICADO, J. , et al., "Fitness Cost of Escape Mutations in p24 Gag in Association with Control of Human Immunodeficiency Virus Type 1", <u>Journal of Virology</u> , 80(7), (2006),3617-3623	
		MASCOLA, J. , et al., "Potent and Synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12", <u>J. Virol Vol. 71 (10)</u> , (1997),7198-7206	
		OKUDA, K. , "DNA Vaccination Followed by Macromolecular Multicomponent Peptide Vaccination Against HIV-1 Induces Strong Antigen-Specific Immunity", <u>Vaccine</u> , 15(10), (1997),1049-1056	
		RAMSHAW, I. A., "The Prime-Boost Strategy: Exciting Prospects for Improved Vaccination", <u>Immunology Today</u> , 21(4), (2000),163-165	
		TRKOLA, A. , et al., "Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.", <u>Nat Med.</u> , 11(6), (Jun., 2005),615-22	

EXAMINER

/Jeffrey Parkin/

DATE CONSIDERED

09/06/2008

Substitute Disclosure Statement Form (PTO-1448)

\* EXAMINER: Initial if reference considered, whether or not citation is to conform with MPEP 808. Draw line through citation if not to conform and not considered. Include copy of this form with next communication to applicant. For clarity, include citation designation (e.g., (1998)) and page number in parentheses. If English translation is required, please indicate. If English translation is required, please indicate.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/048,072
Filing Date	January 25, 2002
First Named Inventor	Franchini, Genoveffa
Group Art Unit	1648
Examiner Name	Parkin, Jeffrey

Sheet 3 of 3

Attorney Docket No: 1662.018US1

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		VON GEGERFELT, A. S., et al., "Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization.", J Virol., 81(4), (Feb., 2007), 1972-9	

EXAMINER

/Jeffrey Parkin/

DATE CONSIDERED

09/06/2008

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's office citation designation (book, journal, etc.) and serials to page, check mark, keep if English language translation is published.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./